Bioidentical hormone therapy: A panacea that lacks supportive evidence

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 4, 2008, Pages 400-407

  Boothby, Lisa A ^a,b,e   Doering, Paul L ^c,d  

^a AUBURN UNIVERSITY   (United States)

^b Drug Information   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d SHANDS Drug Information and Pharmacy Resource Center   (United States)

^e BCPS   (United States)

Author keywords

Bioidentical hormone therapy; Compounding; Estriol; Pharmacy; Progesterone

Indexed keywords

ANDROGEN; CHLORMADINONE ACETATE; CLIMARAPRO; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRATEST; ESTRATSET HS; ESTRIOL; ESTROGEN; ETONOGESTREL; FEMHRT; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HORMONE; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MEGESTROL ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; PLACEBO; PREGNANE DERIVATIVE; PROGESTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROMEGESTROL ACETATE;

ABDOMINAL CRAMP; BIOIDENTICAL HORMONE THERAPY; BONE DENSITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; CRYING; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRY EYE; DRY SKIN; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; INSOMNIA; LIBIDO DISORDER; LOW DRUG DOSE; MEDICAL PROFESSION; MEMORY DISORDER; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; MENTAL INSTABILITY; NIGHT SWEAT; OBESITY; OSTEOLYSIS; PHARMACIST; PHARMACY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STRESS; UNITED STATES; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; ADULT; ARTICLE; DRUG FORMULATION; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FEMALE; STANDARD;

ADULT; DRUG APPROVAL; DRUG COMPOUNDING; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; PROGESTINS; UNITED STATES;

EID: 58149229531     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283081ae9     Document Type: Review

References (34)

1. EgglestonE. Some curious colonial remedies.Am Hist Rev 1899; 5:199-206.
2. ACOG Committee on Gynecologic Practice. ACOG committee opinion number 322. Compounded bioidentical hormones. Obstet Gynecol 2005; 106: 1139-1140.
3. The total solution for developing a BHRT market. The complete hormone makeover, Volumes 1 and 2. Elan Digital Media, Narrated by Donna White, Naturopathic Doctor; 2004.
4. U.S. Food and Drug Administration. Bio-identicals: sorting myths from facts. Available from http://www.fda.gov/consumer/updates/bioidenti-cals040808. html. [Updated 8 April 2008]
5. Sites CK. Bioidentical hormones for menopausal therapy. Womens Health 2008; 4:163-171.
6. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2002; 41:1 -6.
7. Chatterton RT Jr, Mateo ET, Hou N, et al. Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women. J Endocrinol 2005; 186:77-84.
8. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004; 11:356-467.
9. Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health 2007; 16:600-631.
10. Department of Health and Human Services, National Heart, Lung, and Blood Institute, National Institute of Health. Questions and answers about the women's health initiative post menopausal hormone therapy trials. Available from http://www.nhlbi.nih.gov/whi/index.html. [Updated 4 March 2008] [Cited 23 April 2008]
11. Feil PD, Miljković M, Bardin CW. Medroxyprogesterone acetate: a steroid with potent progestational activity but low receptor affinity in the guinea pig uterus. Endocrinology 1976; 98:1508-1515.
12. Kontula K, Janne O, Vihko R, et al. Progesterone-binding proteins: in vitro binding and biological activity of different steroidal ligands. Acta Endocrinol (Copenh) 1975; 78:574-592.
13. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274:51 -57.
14. Mantovani G, Gramignano G, Mais V, et al. Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review. Eur J Obstet Gynecol Reprod Biol 2007; 131:238-239.
15. Mantovani G, Madeddu C, Maccio A, et al. Cancer-related anorexia/ cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004; 13:1651-1659.
16. Cowan LD, Gordis L, Tonascia JA, et al. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981; 114:209-217.
17. Pappo I, Lerner-Giva L, Halevy A. The possible association between IVF and breast cancer incidence. Ann Surg Oncol 2008; 15:1048-1055; DOI: 10.1245/s10434-007-9800-2.
18. Terry KL, Willett WC, Rich-Edwards JW, et al. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006; 166:2484-2489.
19. Gabriel SR, Carmona L, Roque M, et al. Hormone replacement therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev 2005:CD002229.
20. HeissG, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036-1045.
21. Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf) 2008; 68:355-360.
22. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-845.
23. DiPiro JT. Pharmacotherapy: a pathophysiologic approach. 6th ed. McGraw-Hill; 2005.
24. Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically; 2008. [Accessed 25 March 2008]
25. e-Facts (facts and comparisons) [Internet database]. Updated periodically; 2008. [Accessed 25 March 2008]
26. Lexi-Comp, Inc. [Internet database]. Updated periodically; 2008. [Accessed 25 March 2008]
27. Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer asso-ciated with 'bioidentical' hormone replacement therapy. Med J Aust 2007; 187:244-245.
28. Farquhar CM, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005; 20:CD004143.
29. Moandas B, Mehta JL. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. Curr Opin Cardiol 2007; 22:434-442.
30. Rebbeck TR, Troxel AB, Norman S, et al. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 2007; 166: 1392-1399.
31. van Haaften M, Donker GH, Sie-Go DM, et al. Biochemical and histological effects of estriol and estradiol applications on the endometrium, myometrium, and vagina of post menopausal women. Gynecol Endocrinol 1997; 11:175- 185.
32. Mady EA, Ramadan EE, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 2000; 16:151-157.
33. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005:CD004509.
34. APhA response to the Wyeth petition. Available from http://www.iacprx. org/site/DocServer/APhA-Comments-on-2005P-0411.pdf?docID=1601. [Accessed 18 December 2007]